Patient characteristics at baseline
| Donors (n = 25) . | . |
|---|---|
| Age, median in y (range) | 55 (20-69) |
| Sex, male, n (%) | 18 (72) |
| HLA-match, n (%) | |
| Matched sibling | 18 (72) |
| Haploidentical | 7 (28) |
| Donors (n = 25) . | . |
|---|---|
| Age, median in y (range) | 55 (20-69) |
| Sex, male, n (%) | 18 (72) |
| HLA-match, n (%) | |
| Matched sibling | 18 (72) |
| Haploidentical | 7 (28) |
| Recipients (n = 25) . | . |
|---|---|
| Age, median in y (%) | 58 (26-71) |
| Sex, male, n (%) | 15 (60) |
| Disease, n (%) | |
| AML | 16 (64) |
| ALL | 4 (16) |
| MDS | 3 (12) |
| MPN | 1 (4) |
| Hodgkin lymphoma | 1 (4) |
| Conditioning regimen, n (%) | |
| Fludarabine + busulfan 2 (RIC) or busulfan 4 (MAC) | 11 (50) |
| Fludarabine/cytoxan/TBI | 7 (32) |
| Busulfan/cytoxan | 3 (14) |
| cytoxan/TBI | 1 (5) |
| Recipients (n = 25) . | . |
|---|---|
| Age, median in y (%) | 58 (26-71) |
| Sex, male, n (%) | 15 (60) |
| Disease, n (%) | |
| AML | 16 (64) |
| ALL | 4 (16) |
| MDS | 3 (12) |
| MPN | 1 (4) |
| Hodgkin lymphoma | 1 (4) |
| Conditioning regimen, n (%) | |
| Fludarabine + busulfan 2 (RIC) or busulfan 4 (MAC) | 11 (50) |
| Fludarabine/cytoxan/TBI | 7 (32) |
| Busulfan/cytoxan | 3 (14) |
| cytoxan/TBI | 1 (5) |
ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; MAC, myeloablative conditioning; MDS, myelodysplastic syndrome; MPN, myeloproliferative neoplasm; RIC, reduced intensity conditioning; TBI, total body irradiation.